Prevalence, risk factors, and impact on outcome of cytomegalovirus replication in serum of Cambodian HIV-infected patients (2004-2007)

Journal of Acquired Immune Deficiency Syndromes

Volumn 51, Issue 4, 2009, Pages 486-491

  Micol, Romain ^a,b   Buchy, Philippe ^c   Guerrier, Gilles ^a   Duong, Veasna ^c   Ferradini, Laurent ^d   Dousset, Jean Philippe ^e   Guerin, Philippe J ^f   Balkan, Suna ^d   Galimand, Julie ^b   Chanroeun, Hak ^g   Lortholary, Olivier ^b   Rouzioux, Christine ^b   Fontanet, Arnaud ^a   Leruez Ville, Marianne ^a  

^a INSTITUT PASTEUR   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c INSTITUT PASTEUR DU CAMBODGE   (Cambodia)

^d MÉDECINS SANS FRONTIÈRES   (Switzerland)

^e Hôpital Kosamak   (Cambodia)

^f EPICENTRE   (France)

^g Hopital Calmette   (Cambodia)

Author keywords

Cambodia; CMV; HIV; Mortality; PCR; Prevalence

Indexed keywords

ANTIRETROVIRUS AGENT; VIRUS DNA;

ADULT; ARTICLE; BLOOD CELL COUNT; CAMBODIA; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; COHORT ANALYSIS; CYTOMEGALOVIRUS; DIAGNOSTIC TEST; FOLLOW UP; GOLD STANDARD; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL EDUCATION; MORTALITY; NONHUMAN; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; TREATMENT OUTCOME; VIROTHERAPY; VIRUS LOAD; VIRUS REPLICATION;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CAMBODIA; CD4 LYMPHOCYTE COUNT; CYTOMEGALOVIRUS; DNA, VIRAL; FEMALE; HIV INFECTIONS; HUMANS; MALE; PREVALENCE; RISK FACTORS; VIRUS REPLICATION;

EID: 68049147317     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181a254c2     Document Type: Article

References (20)

1. Spector SA,Wong R, Hsia K, et al. Plasma cytomegalovirus (CMV) DNA load predicts CMV disease and survival in AIDS patients. J Clin Invest. 1998;101:497-502. (Pubitemid 28067348)
2. Wohl DA, Zeng D, Stewart P, et al. Cytomegalovirus viremia, mortality, and end-organ disease among patients with AIDS receiving potent antiretroviral therapies. J Acquir Immune Defic Syndr. 2005;38: 538-544. (Pubitemid 40524475)
3. Deayton JR, Prof Sabin CA, Johnson MA, et al. Importance of cytomegalovirus viraemia in risk of disease progression and death in HIV-infected patients receiving highly active antiretroviral therapy. Lancet. 2004;363:2116-2121. (Pubitemid 38844151)
4. Reus S, Portilla J, Gimeno A, et al. [Predictors of progression and death in patients with advanced HIV infection in the era of highly active antiretroviral therapy]. Enferm Infecc Microbiol Clin. 2004;22:142-149.
5. Micol R, Lortholary O, Sar B, et al. Prevalence, determinants of positivity, and clinical utility of cryptococcal antigenemia in Cambodian HIV-infected patients. J Acquir Immune Defic Syndr. 2007;45:555-559. (Pubitemid 47294928)
6. Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis. 2002;34:7-14. (Pubitemid 33152659)
7. Leruez-Ville M, Ouachee M, Delarue R, et al. Monitoring cytomegalovirus infection in adult and pediatric bone marrow transplant recipients by a real-time PCR assay performed with blood plasma. J Clin Microbiol. 2003;41:2040-2046. (Pubitemid 36576532)
8. Bowen EF, Sabin CA, Wilson P, et al. Cytomegalovirus (CMV) viraemia detected by polymerase chain reaction identifies a group of HIV-positive patients at high risk of CMV disease. AIDS. 1997;11:889-893. (Pubitemid 27226412)
9. Urwijitaroon Y, Teawpatanataworn S, Kitjareontarm A. Prevalence of cytomegalovirus antibody in Thai-northeastern blood donors. Southeast Asian J Trop Med Public Health. 1993;24(Suppl 1):180-182.
10. Hansen KK, Ricksten A, Hofmann B, et al. Detection of cytomegalovirus DNA in serum correlates with clinical cytomegalovirus retinitis in AIDS. J Infect Dis. 1994;170:1271-1274. (Pubitemid 24328635)
11. Nokta MA, Holland F, De Gruttola V, et al. Cytomegalovirus (CMV) polymerase chain reaction profiles in individuals with advanced human immunodeficiency virus infection: relationship to CMV disease. J Infect Dis. 2002;185:1717-1722. (Pubitemid 34615464)
12. Hodge WG, Boivin JF, Shapiro SH, et al. Laboratory-based risk factors for cytomegalovirus retinitis. Can J Ophthalmol. 2004;39:733-745. (Pubitemid 40115575)
13. Sing GK, Ruscetti FW. Preferential suppression of myelopoiesis in normal human bone marrow cells after in vitro challenge with human cytomegalovirus. Blood. 1990;75:1965-1973.
14. Rafailidis PI, Mourtzoukou EG, Varbobitis IC, et al. Severe cytomegalovirus infection in apparently immunocompetent patients: a systematic review. Virol J. 2008;5:47.
15. Heiden D, Ford N, Wilson D, et al. Cytomegalovirus retinitis: the neglected disease of the AIDS pandemic. PLoS Med. 2007;4:e334.
16. French MA, Lenzo N, John M, et al. Immune restoration disease after the treatment of immunodeficient HIV-infected patients with highly active antiretroviral therapy. HIV Med. 2000;1:107-115.
17. Karavellas MP, Plummer DJ, Macdonald JC, et al. Incidence of immune recovery vitritis in cytomegalovirus retinitis patients following institution of successful highly active antiretroviral therapy. J Infect Dis. 1999;179: 697-700.
18. Ortega-Larrocea G, Espinosa E, Reyes-Teran G. Lower incidence and severity of cytomegalovirus-associated immune recovery uveitis in HIV-infected patients with delayed highly active antiretroviral therapy. AIDS. 2005;19:735-738. (Pubitemid 40593082)
19. Wohl DA, Kendall MA, Owens S, et al. The safety of discontinuation of maintenance therapy for cytomegalovirus (CMV) retinitis and incidence of immune recovery uveitis following potent antiretroviral therapy. HIV Clin Trials. 2005;6:136-146. (Pubitemid 41341728)
20. Martin DF, Sierra-Madero J, Walmsley S, et al. A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis. N Engl J Med. 2002;346:1119-1126. (Pubitemid 34984602)